QQQ0.21%

Trending

ADBE5.87%

home Symbol NUVBnews

NUVBNuvation Bio Inc - Ordinary Shares - Class A

$4.76

$0.18

(3.93%)

Today

Closed $4.76

$0.02

(0.42%)

After Hours

Updated: 07:56 PM EDT

EarningsAug 6

Mkt Cap$1.6B

Vol3.46M

Fundamentals

Mkt Cap

$1.6B

Volume

52W High

$9.75

52W Low

$1.57

PE Ratio

-11.12

Avg. Volume

4.53M

EPS (Annual)

-$0.5991

Rev/Employee

$211,080.54

Earnings

Aug 06

Info

News

all

press releases

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio to Present at the Jefferies Global Healthcare Conference Nuvation Bio to Present at the Jefferies Global Healthcare Conference PR Newswire NEW YORK, May 27, 2026 NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of...

PR Newswire

More News

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer...

PR Newswire

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio to Collaborate with Thermo Fisher...

PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of...

PR Newswire

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio to Participate in Upcoming Investor Conferences Nuvation Bio to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, May 5, 2026 NEW YORK, May 5, 2026 /PRNewswire...

PR Newswire

Nuvation Bio's (NUVB) "Outperform" Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed an 'outperform' rating and set a $20.00 target price on shares of Nuvation Bio in a report on Tuesday...

MarketBeat

Nuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from Wedbush

Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Tuesday...

MarketBeat

Nuvation Bio Q1 Earnings Call Highlights

Nuvation Bio (NYSE:NUVB) executives said the company made continued commercial progress with ROS1-positive non-small cell lung cancer (NSCLC) therapy Ibtrozi during the first quarter of 2026...

MarketBeat

Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates

Nuvation Bio (NUVB) delivered earnings and revenue surprises of -91.30% and +0.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks

Nuvation Bio (NYSE:NUVB) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Nuvation Bio (NYSE:NUVB - Get Free Report) issued its earnings results on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.04. The business had revenue of $83.23 million for the quarter, compared to analyst estimates of...

MarketBeat

...

Advertisement|Remove ads.